NXL

BEARISH

$0.51 Live

Nexalin Technology, Inc. · NASDAQ

Target $2.0 (+292.9%)

$0.33 52W Range $2.0

NXL Nexalin Technology, Inc. - Fundamental Analysis

BEARISH

Console Chart News

NXL Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$0.51

Analyst Target

$2.0

+292.9% Upside

52W High

$2.0

52W Low

$0.33

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 16, 2026

Market cap

$10.48M

P/E

N/A

ROE

-221.5%

Profit margin

N/A

Debt/Equity

N/A

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

90%

NXL exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company shows explosive year-over-year revenue growth of 532.50%, this is completely offset by a catastrophic operating margin of -1403.86% and negative ROE of -221.50%. The stock is currently trading at an exorbitant Price/Sales ratio of 34.73, which is unsustainable given the lack of profitability. Despite a recent short-term price bounce and a single analyst's 'buy' rating, the underlying deterministic data suggests a high risk of capital impairment.

Key Strengths

Exceptional YoY revenue growth (532.50%)

Strong gross margins (79.65%) indicating product value

Healthy short-term liquidity (Current Ratio 4.84)

Recent short-term positive price momentum (1W +45.4%)

Improving YoY EPS growth (+53.6%) despite remaining negative

Key Risks

Extreme operational inefficiency (Operating Margin -1403.86%)

Critical financial health failure (Piotroski F-Score 1/9)

Severe valuation disconnect (P/S Ratio 34.73)

Micro-cap volatility and low market capitalization ($0.01B)

Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Piotroski F-Score 1/9, Negative Operating Margins, Extreme P/S Ratio, Hyper-growth Revenue

Confidence

95%

Value

10/100

Ref P/E N/A, P/S 34.73, Graham Number None

Positives

No standout positives identified.

Watchpoints

P/S of 34.73 is extreme
No Graham Number due to negative earnings
P/B of 2.61 is high for a non-profitable micro-cap

Future

55/100

Ref Revenue Growth 532.50%

Positives

Massive revenue growth (532%)
High gross margins

Watchpoints

Unable to scale revenue into profit
Negative forward P/E

Past

15/100

Ref 1Y Return -70.6%

Positives

Recent 1-month recovery

Watchpoints

1Y Change -70.6%
Consistent earnings misses

Health

12/100

Ref Piotroski F-Score 1/9

Positives

Strong Current Ratio (4.84)

Watchpoints

Piotroski F-Score 1/9
ROE -221.50%
ROA -118.41%

Dividend

0/100

Ref Dividend Yield N/A

Positives

No standout positives identified.

Watchpoints

No dividend paid
No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$0.51

Analyst Target

$2.0

Upside/Downside

+292.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for NXL and closest competitors.

Updated 2026-04-15

Company	5Y	3Y	1Y	6M	1M	1W
NXL Nexalin Technology, Inc. Primary	-77.4%	-35.6%	-70.6%	-64.9%	+25.1%	+45.4%
BFRI Biofrontera Inc. Peer	-99.0%	-93.2%	-14.4%	-1.0%	+3.1%	-1.7%
NCEL NewcelX Ltd. Peer	-99.8%	-99.6%	-82.6%	-85.8%	-5.6%	+21.1%
BNGO Bionano Genomics, Inc. Peer	-100.0%	-99.8%	-64.6%	-35.8%	+0.9%	+3.6%
GDTC CytoMed Therapeutics Limited Peer	-75.0%	-75.0%	-63.5%	-55.6%	-5.7%	+1.2%

NXL

Nexalin Technology, Inc.

Primary

-77.4%

-35.6%

-70.6%

-64.9%

+25.1%

+45.4%

BFR

Biofrontera Inc.

Peer

-99.0%

-93.2%

-14.4%

-1.0%

+3.1%

-1.7%

NCE

NewcelX Ltd.

Peer

-99.8%

-99.6%

-82.6%

-85.8%

-5.6%

+21.1%

BNG

Bionano Genomics, Inc.

Peer

-100.0%

-99.8%

-64.6%

-35.8%

+0.9%

+3.6%

GDT

CytoMed Therapeutics Limited

Peer

-75.0%

-63.5%

-55.6%

-5.7%

+1.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-1.64

N/A

2.61

34.73

22.39

-0.81

$10.48M

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -1403.86%

Gross Margin 79.65%

ROE -221.5%

ROA -118.41%

Growth

Revenue and earnings growth rates

Revenue Growth +532.5%

Earnings Growth N/A

Q/Q Revenue Growth +532.46%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

N/A

Current Ratio

4.84

Strong

Quick Ratio

4.29

Excellent

Cash/Share

$0.18

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

87.8%

Op. Margin

-1403.9%

Net Margin

-1382.6%

Total Assets

$0.0B

Liabilities

$0.0B

Equity

$0.0B

Debt/Equity

0.24x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

103%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-25

$-0.13

-8.3% surprise

2025-11-14

$-0.13

-8.3% surprise

2025-08-06

$-0.1

+28.6% surprise

2025-05-13

$-0.15

-50.0% surprise

Healthcare Sector Comparison

Comparing NXL against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)

Return on Equity (ROE)

-221.5%

This Stock

-100.15%

Sector Avg

+121.2% (Excellent)

Revenue Growth

532.5%

This Stock

121.05%

Sector Avg

+339.9% (Fast Growth)

Current Ratio

4.84

This Stock

4.55

Sector Avg

+6.5% (Better)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
NXL Nexalin Technology, Inc.	BEARISH	$10.48M	-	-221.5%	-%	$0.51
BFRI Biofrontera Inc.	BEARISH	$9.97M	-	-1191.7%	-47.3%	$0.86	Compare
NCEL NewcelX Ltd.	BEARISH	$11.49M	-	-%	-%	$2.52	Compare
BNGO Bionano Genomics, Inc.	BEARISH	$11.7M	-	-78.2%	-134.4%	$1.15	Compare
GDTC CytoMed Therapeutics Limited	BEARISH	$11.83M	-	-50.3%	-%	$1.0	Compare

NXL Nexalin Technology, Inc.

BEARISH

Mkt Cap

$10M

P/E

ROE

-221.5%

Price

$0.51

BFRI Biofrontera Inc.

Compare with NXL

Compare with NXL

BNGO Bionano Genomics, Inc.

Compare with NXL

Compare with NXL

Past News Coverage

Recent headlines mentioning NXL from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

NXL

NXL Nexalin Technology, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Past News Coverage

Wait — Don't Miss Out!